Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope

Front Oncol. 2022 Sep 8:12:1021870. doi: 10.3389/fonc.2022.1021870. eCollection 2022.

Authors

Christine Galustian¹, Angus Dalgleish², Mark Bodman-Smith², Sergei Kusmartsev³, Prokar Dasgupta¹

Affiliations

¹ Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
² Institute for Infection and Immunology, St. George's, University of London, London, United Kingdom.
³ Department of Urology, School of Medicine, University of Florida, Gainesville, FL, United States.

No abstract available

Keywords: CAR T cell therapy; Castration-resistant Prostate Cancer; Immunotherapy; Prostate Cancer; Provenge®; Tumor microenvironment.

Publication types

Editorial